Founded in 2012, today, Immacule Lifesciences has become a renowned name in the pharmaceutical industry. At Immacule, our dedicated team of scientists is here to provide you with customized services, supported by our extensive network of capabilities and resources. No matter where you are, as an end-to-end pharmaceutical service provider and partner we offer quality, speed and value by combining our technical competencies and cost-effective solutions. We are backward integrated in pharmaceutical research and development and our focus ranges from the classification and development, to the commercialization of complex liquid (aqueous/non aqueous) and lyophilized injectables in vials and ampoules, with robust capabilities for terminal sterilization as well as aseptically filled injectables. As a CDMO we are rapidly capturing the highly competitive sterile US market, in collaboration with our partners we have received 15 ANDA approvals, have 14 ANDAs under review and a filing target of 50+ by 2025. Immacule is focusing on First to File 505(b)(2) submissions, NCEs & complex generics niche products scale-up, exhibit batches & commercial manufacturing support services to its global clients.
Solid Dosage Facility (General and Hormonal Block)
Solid Dosage Facility (General Tablets/Capsules and Levothyroxine Tablets)
Contract Research Organization